Enanta is a biotechnology company that discovers and develops small-molecule drugs for virology and immunology using chemistry-driven research. The company generates revenue primarily through tiered double-digit royalties on AbbVie's marketed hepatitis C therapy MAVYRET/MAVIRET, which contains the protease inhibitor glecaprevir discovered by Enanta, while also building wholly-owned drug candidates in respiratory viral diseases and type 2 inflammatory conditions across programs targeting respiratory syncytial virus, COVID-19, hepatitis B, chronic urticaria, and atopic dermatitis. Enanta operates without direct commercial infrastructure, relying on in-house chemistry and molecular biology expertise to discover candidates and then partnering with larger pharmaceutical companies for clinical development and commercialization while retaining royalty income and commercial rights.